文献速递帕金森病与运动障碍

促糖酵解α-1受体阻滞剂与帕金森病风险的相关性

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2021-01-01

该队列研究基于丹麦全国登记库(1996–2017)与美国Truven MarketScan数据库(2001–2017),纳入无帕金森病且新启用特拉唑嗪/多沙唑嗪/阿夫唑嗪或坦索罗辛的男性,经倾向评分匹配后比较帕金森病发生风险。结果显示,与坦索罗辛相比,特拉唑嗪/多沙唑嗪/阿夫唑嗪使用者帕金森病风险更低,且随用药时间延长呈剂量-反应关系。

要点

  • 与坦索罗辛相比,特拉唑嗪/多沙唑嗪/阿夫唑嗪使用者帕金森病风险降低。
  • 丹麦队列HR 0.88(95%CI 0.81-0.98),Truven队列HR 0.63(95%CI 0.58-0.69)。
  • 两队列均见剂量-反应关系,长期使用HR更低。

核心结论

  • 特拉唑嗪/多沙唑嗪/阿夫唑嗪使用者较坦索罗辛使用者帕金森病风险更低。

研究设计与样本

  • 丹麦登记库纳入52 365对匹配用户,全部为男性,平均(SD)年龄67.9(10.4)岁。
  • Truven数据库纳入94 883对匹配用户,全部为男性,平均(SD)年龄63.8(11.1)岁。
  • 纳入无帕金森病且新启用特拉唑嗪/多沙唑嗪/阿夫唑嗪或坦索罗辛、用药开始后随访至少1年的男性。

主要发现

  • 丹麦队列中,特拉唑嗪/多沙唑嗪/阿夫唑嗪使用者发生帕金森病的HR为0.88(95%CI 0.81-0.98)。
  • Truven队列中,特拉唑嗪/多沙唑嗪/阿夫唑嗪使用者发生帕金森病的HR为0.63(95%CI 0.58-0.69)。
  • 丹麦队列按用药时长分层:短期HR 0.95(95%CI 0.84-1.07),中期HR 0.88(95%CI 0.77-1.01),长期HR 0.79(95%CI 0.66-0.95)。
  • Truven队列按用药时长分层:短期HR 0.70(95%CI 0.64-0.76),中期HR 0.58(95%CI 0.52-0.64),长期HR 0.46(95%CI 0.36-0.57)。

临床怎么用

  • 对于因良性前列腺增生或未特指排尿问题需用α-1阻滞剂的男性,选择特拉唑嗪/多沙唑嗪/阿夫唑嗪可能与较低的帕金森病风险相关。
  • 临床决策时可结合剂量-反应关系考虑用药时长对帕金森病风险的潜在影响。

局限性

  • 研究为观察性队列,不能确立因果关系。
  • 结论需未来工作进一步评估该关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Parkinson disease (PD) is a common neurodegenerative disease. A treatment that prevents or delays development of PD is a critical unmet need. Terazosin and closely related drugs were recently discovered to enhance glycolysis and reduce PD progression in animal models and human clinical databases. OBJECTIVE: To determine whether use of terazosin, doxazosin, and alfuzosin is associated with a decreased risk of developing PD. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used active comparator control and propensity score-matched data from Danish nationwide health registries, including the Danish National Prescription Registry, the Danish National Patient Registry, and the Danish Civil Registration System, from January 1996 to December 2017 and data from the Truven Health Analytics MarketScan database from January 2001 to December 2017. Men without PD who newly initiated terazosin/doxazosin/alfuzosin therapy or tamsulosin therapy, which is used for a similar indication (benign prostatic hyperplasia or unspecified urinary problems) but does not enhance glycolysis, and had at least 1 year of follow-up after medication start were included. In Denmark, the database included all residents, while the Truven database is a compilation of insurance claims across the US. Data were analyzed from February 2019 to July 2020. EXPOSURES: Patients who used terazosin/doxazosin/alfuzosin vs tamsulosin. Additional dose-response analyses were carried out. MAIN OUTCOMES AND MEASURES: Differences in the hazard of developing PD identified by diagnoses or use of PD-specific medications between patients who ever used terazosin/doxazosin/alfuzosin or tamsulosin. RESULTS: A cohort of 52 365 propensity score-matched pairs of terazosin/doxazosin/alfuzosin and tamsulosin users were identified in the Danish registries, of which all were male and the mean (SD) age was 67.9 (10.4) years, and 94 883 propensity score-matched pairs were identified in the Truven database, of which all were male and the mean (SD) age was 63.8 (11.1) years. Patients in the Danish cohort who used terazosin/doxazosin/alfuzosin had a hazard ratio (HR) for developing PD of 0.88 (95% CI, 0.81-0.98), and patients in the Truven cohort had an HR of 0.63 (95% CI, 0.58-0.69). There was a dose-response association with short-duration, medium-duration, and long-duration use of terazosin/doxazosin/alfuzosin users having a decreasing HR in both the Danish cohort (short: HR, 0.95; 95% CI, 0.84-1.07; medium: HR, 0.88; 95% CI, 0.77-1.01; long: HR, 0.79; 95% CI, 0.66-0.95) and Truven cohort (short: HR, 0.70; 95% CI, 0.64-0.76; medium: HR, 0.58; 95% CI, 0.52-0.64; long: HR, 0.46; 95% CI, 0.36-0.57). CONCLUSIONS AND RELEVANCE: These data suggest that users of terazosin/doxazosin/alfuzosin are at lower hazard of developing PD compared with users of tamsulosin. Future work is needed to further assess this association.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Simmering JE, Welsh MJ, Liu L, et al. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021. PMID: 33523098. doi:10.1001/jamaneurol.2020.5157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。